Download PDF
Aktuelle Neurologie 2015; 42(05): 293-294
DOI: 10.1055/s-0035-1552637
Kompetenznetz Multiple Sklerose
© Georg Thieme Verlag KG Stuttgart · New York

Aktuelles aus der Forschung

T. Menge
1   Zentrum Neurologie und Neuropsychiatrie, LVR-Klinikum, Heinrich-Heine-Universität, Düsseldorf
2   Neurologische Klinik, Heinrich-Heine-Universität, Düsseldorf
,
G. Meyer zu Hörste
3   Center for Neurologic Diseases, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
› Author Affiliations
Further Information

Publication History

Publication Date:
30 June 2015 (online)

Also available at
    Permissions and Reprints

Diverse neue therapeutische Ansätze im Tiermodell

Trotz aller rezenten Fortschritte in der pharmakologischen Therapie der MS besteht unverändert ein Bedarf für Therapien der neurodegenerativen Komponente. Ein Ansatz, der endogene Remyelinisierung fördert und axonale Degeneration reduziert, könnte neue Optionen insbesondere in chronisch-progredienten Verlaufsformen der MS schaffen. Steroidhormone – unter anderem Östrogene – können die Myelinisierung beeinflussen und unter bestimmten Voraussetzungen auch neuroprotektiv wirken.

 

  • Literatur

  • 1 Moore SM et al. Multiple functional therapeutic effects of the estrogen receptor beta agonist indazole-Cl in a mouse model of multiple sclerosis. Proc Natl Acad Sci USA 2014; 111: 18061-18066
    CrossrefPubMedGoogle Scholar
  • 2 Tullius SG et al. NAD+ protects against EAE by regulating CD4+ T-cell differentiation. Nat Commun 2014; 5: 5101
    CrossrefPubMedGoogle Scholar
  • 3 Rumble JM et al. Neutrophil-related factors as biomarkers in EAE and MS. J Exp Med 2015; 212: 23-35
    CrossrefPubMedGoogle Scholar
  • 4 Stilund M et al. Biomarkers of Inflammation and Axonal Degeneration/Damage in Patients with Newly Diagnosed Multiple Sclerosis: Contributions of the Soluble CD163 CSF/Serum Ratio to a Biomarker Panel. PLoS One 2015; 10: e0119681
    CrossrefPubMedGoogle Scholar
  • 5 Modvig S et al. Cerebrospinal fluid levels of chitinase 3-like 1 and neurofilament light chain predict multiple sclerosis development and disability after optic neuritis. Mult Scler 2015; Feb 19. pii: DOI: 1352458515574148.
    PubMedGoogle Scholar
  • 6 Teunissen CE, Khalil M. Neurofilaments as biomarkers in multiple sclerosis. Mult Scler 2012; 18: 552-556
    CrossrefPubMedGoogle Scholar
  • 7 Gunnarsson M et al. Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. Ann Neurol 2011; 69: 83-89
    CrossrefPubMedGoogle Scholar
  • 8 Kuhle J et al. Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis. Neurology 2015; 84: 1639-1643
    CrossrefPubMedGoogle Scholar
  • 9 Disanto G et al. Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome. J Neurol Neurosurg Psychiatry 2015; pii: jnnp-2014-309690 DOI: 10.1136/jnnp-2014-309690.
    PubMedGoogle Scholar
  • 10 Komori M et al. Cerebrospinal fluid markers reveal intrathecal inflammation in progressive multiple sclerosis. Ann Neurol 2015; DOI: 10.1002/ana.24408.
    PubMedGoogle Scholar